StockData
Veracyte, Inc. logo

Veracyte, Inc. (VCYT) stock

VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3034% below fair value
$24.23+0.22 (+0.92%)

Close on Nov 17, 2026Market cap $1.95BP/E 17.3Yield –

Veracyte cash

Cash and short-term investments held at the end of each period.

Veracyte's cash was $299.52M at Jun 30, 2026. For fiscal 2025 it was $412.89M, up 42.7% from the year before. Over ten years it grew 26.4% a year on average. The highest annual figure on record is $412.89M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$412.89M+42.7%
FY2024Dec 31, 2024$289.40M+33.7%
FY2023Dec 31, 2023$216.50M+21.0%
FY2022Dec 31, 2022$178.90M+2.8%
FY2021Dec 31, 2021$173.95M-50.3%
FY2020Dec 31, 2020$349.97M+118.8%
FY2019Dec 31, 2019$159.92M+103.5%
FY2018Dec 31, 2018$78.60M+127.9%
FY2017Dec 31, 2017$34.49M-42.5%
FY2016Dec 31, 2016$59.94M+50.6%
FY2015Dec 31, 2015$39.81M+13.7%
FY2014Dec 31, 2014$35.01M-50.8%
FY2013Dec 31, 2013$71.22M+408.6%
FY2012Dec 31, 2012$14.00M+85.1%
FY2011Dec 31, 2011$7.57M+172.6%
FY2010Dec 31, 2010$2.78M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$299.52M+35.4%
Q1 FY2026Mar 31, 2026$263.14M+40.1%
Q4 FY2025Dec 31, 2025$412.89M+42.7%
Q3 FY2025Sep 30, 2025$315.57M+14.7%
Q2 FY2025Jun 30, 2025$221.15M-6.7%
Q1 FY2025Mar 31, 2025$187.77M-10.7%
Q4 FY2024Dec 31, 2024$289.40M+33.7%
Q3 FY2024Sep 30, 2024$275.16M+35.3%
Q2 FY2024Jun 30, 2024$237.00M+23.4%
Q1 FY2024Mar 31, 2024$210.27M+17.7%
Q4 FY2023Dec 31, 2023$216.50M+21.0%
Q3 FY2023Sep 30, 2023$203.33M+19.0%
Q2 FY2023Jun 30, 2023$192.03M+24.5%
Q1 FY2023Mar 31, 2023$178.64M+8.7%
Q4 FY2022Dec 31, 2022$178.90M+2.8%
Q3 FY2022Sep 30, 2022$170.86M+3.7%
Q2 FY2022Jun 30, 2022$154.20M-53.0%
Q1 FY2022Mar 31, 2022$164.36M-49.4%
Q4 FY2021Dec 31, 2021$173.95M-50.3%
Q3 FY2021Sep 30, 2021$164.78M-52.3%
Q2 FY2021Jun 30, 2021$328.29M+121.7%
Q1 FY2021Mar 31, 2021$324.81M+111.3%
Q4 FY2020Dec 31, 2020$349.97M+118.8%
Q3 FY2020Sep 30, 2020$345.68M+76.1%
Q2 FY2020Jun 30, 2020$148.05M-23.4%
Q1 FY2020Mar 31, 2020$153.74M+124.6%
Q4 FY2019Dec 31, 2019$159.92M+103.5%
Q3 FY2019Sep 30, 2019$196.27M+150.2%
Q2 FY2019Jun 30, 2019$193.25M+693.3%
Q1 FY2019Mar 31, 2019$68.44M+146.6%
Q4 FY2018Dec 31, 2018$78.60M+127.9%
Q3 FY2018Sep 30, 2018$78.45M+87.7%
Q2 FY2018Jun 30, 2018$24.36M-48.4%
Q1 FY2018Mar 31, 2018$27.76M-46.1%
Q4 FY2017Dec 31, 2017$34.49M-42.5%
Q3 FY2017Sep 30, 2017$41.80M+31.9%
Q2 FY2017Jun 30, 2017$47.19M–
Q1 FY2017Mar 31, 2017$51.51M–
Q4 FY2016Dec 31, 2016$59.94M–
Q3 FY2016Sep 30, 2016$31.70M–

More Veracyte figures

See a number that looks wrong?